Role of biomarkers and molecular signaling pathways in acute lung injury
Fundamental & Clinical Pharmacology · 2024-08 · 38 (4) · 640-657
DOI: 10.1111/fcp.12987 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Fundamental & Clinical Pharmacology, online erschienen am 26.01.2024. Verfasst von Pakter Niri und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmaceutical Technology, Defence Research Laboratory (DRL), Defence Research and Development Organisation (DRDO), Tezpur, 784 001, Indi…. Hauptthemen laut MEDLINE: Acute Lung Injury, Signal Transduction, Biomarkers. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 180 Literaturangaben. Gefördert von: Defence Research and Development Organisation, Ministry of Defence, Government of India, University of Calcutta.
Abstract (Originalsprache)
Background
Acute lung injury (ALI) is caused by bacterial, fungal, and viral infections. When pathogens invade the lungs, the immune system responds by producing cytokines, chemokines, and interferons to promote the infiltration of phagocytic cells, which are essential for pathogen clearance. Their excess production causes an overactive immune response and a pathological hyper‐inflammatory state, which leads to ALI. Until now, there is no particular pharmaceutical treatment available for ALI despite known inflammatory mediators like neutrophil extracellular traps (NETs) and reactive oxygen species (ROS).
Objectives
Therefore, the primary objective of this review is to provide the clear overview on the mechanisms controlling NETs, ROS formation, and other relevant processes during the pathogenesis of ALI. In addition, we have discussed the significance of epithelial and endothelial damage indicators and several molecular signaling pathways associated with ALI.
Methods
The literature review was done from Web of Science, Scopus, PubMed, and Google Scholar for ALI, NETs, ROS, inflammation, biomarkers, Toll‐ and nucleotide‐binding oligomerization domain (NOD)‐like receptors, alveolar damage, pro‐inflammatory cytokines, and epithelial/endothelial damage alone or in combination.
Results
This review summarized the main clinical signs of ALI, including the regulation and distinct function of epithelial and endothelial biomarkers, NETs, ROS, and pattern recognition receptors (PRRs).
Conclusion
However, no particular drugs including vaccine for ALI has been established. Furthermore, there is a lack of validated diagnostic tools and a poor predictive rationality of current therapeutic biomarkers. Hence, extensive and precise research is required to speed up the process of drug testing and development by the application of artificial intelligence technologies, structure‐based drug design, in‐silico approaches, and drug repurposing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pharmaceutical Technology, Defence Research Laboratory (DRL), Defence Research and Development Organisation (DRDO), Tezpur, 784 001, India.
- Department of Chemical Technology, University of Calcutta, Kolkata, 700009, India.
- Department of Pharmaceutical Sciences, Dibrugarh University, Dibrugarh, 786004, India.
ORCID-Profile: Pronobesh Chattopadhyay
Förderung
- Defence Research and Development Organisation
- Ministry of Defence, Government of India
- University of Calcutta
- Ministry of Defence
Zitieren
APA
Niri, P., Saha, A., Polopalli, S., Kumar, M., Das, S., & Chattopadhyay, P. (2024). Role of biomarkers and molecular signaling pathways in acute lung injury. Fundamental & Clinical Pharmacology, 38(4), 640-657. https://doi.org/10.1111/fcp.12987
Vancouver
Niri P, Saha A, Polopalli S, Kumar M, Das S, Chattopadhyay P. Role of biomarkers and molecular signaling pathways in acute lung injury. Fundamental & Clinical Pharmacology. 2024;38(4):640-657. doi:10.1111/fcp.12987
BibTeX
@article{Niri2024,
author = {Niri, Pakter and Saha, Achintya and Polopalli, Subramanyam and Kumar, Mohit and Das, Sanghita and Chattopadhyay, Pronobesh},
title = {Role of biomarkers and molecular signaling pathways in acute lung injury},
journal = {Fundamental & Clinical Pharmacology},
year = {2024},
volume = {38},
number = {4},
pages = {640--657},
doi = {10.1111/fcp.12987}
}
EUVIMED